Cargando…
Drug discovery targeting SARS-CoV-2 membrane fusion
Autores principales: | Yang, Kailu, Wang, Chuchu, Kreutzberger, Alex J.B., Ojha, Ravi, Kuivanen, Suvi, Couoh-Cardel, Sergio, Muratcioglu, Serena, Eisen, Timothy J., White, K. Ian, Pfuetzner, Richard, Kuriyan, John, Vapalahti, Olli, Balistreri, Giuseppe, Kirchhausen, Tomas, Brunger, Axel T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Biophysical Society. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912913/ http://dx.doi.org/10.1016/j.bpj.2022.11.1802 |
Ejemplares similares
-
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein
por: Yang, Kailu, et al.
Publicado: (2022) -
Structure-based design of a SARS-CoV-2 Omicron-specific inhibitor
por: Yang, Kailu, et al.
Publicado: (2023) -
Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease
por: Kreutzberger, Alex J.B., et al.
Publicado: (2021) -
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease
por: Kreutzberger, Alex J. B., et al.
Publicado: (2021) -
Complete Protection from SARS-CoV-2 Lung Infection in Mice Through Combined Intranasal Delivery of PIKfyve Kinase and TMPRSS2 Protease Inhibitors
por: Kant, Ravi, et al.
Publicado: (2023)